Seattle

Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors

Retrieved on: 
Wednesday, December 14, 2022

“We are extremely pleased to have Dieter join Umoja as the Chair of our Board of Directors.

Key Points: 
  • “We are extremely pleased to have Dieter join Umoja as the Chair of our Board of Directors.
  • Dieter Weinand added, “With the ENLIGHTen clinical trial underway and Umoja positioned to advance its platforms through multiple collaborations in 2022, this is an exciting time to be joining the Company.
  • He is currently Chairman of the Board of Replimune (REPL), Member of the Board of Directors of Reunion Neuroscience (REUN), Chairman of the Board of Directors of ForeBio, Chairman of the Board of Mnemo, and Executive Chairman of the Board of ZielBioPharma.
  • This press release contains forward-looking statements about Umoja Biopharma, Inc. (the “Company,” “we,” “us,” or “our”).

Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies

Retrieved on: 
Monday, November 21, 2022

Collaborations like this between Umoja and IASO seek to push the next phase of cancer treatment forward.

Key Points: 
  • Collaborations like this between Umoja and IASO seek to push the next phase of cancer treatment forward.
  • We are very pleased to enter a collaboration with Umoja, said Wen (Maxwell) Wang, M.D., Ph.D., Chief Executive Officer of IASO Bio.
  • The benefit of our fully-human CAR constructs to treat patients with hematologic malignancies have been validated in clinical trials of our broad set of targets and indications.
  • Umoja Biopharma, Inc. is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies.

Helicopter Pioneer Frank Robinson Passes

Retrieved on: 
Sunday, November 13, 2022

TORRANCE, Calif., Nov. 13, 2022 /PRNewswire/ --On November 12, 2022 Robinson Helicopter Company bid a final farewell to its founder, Frank Robinson.

Key Points: 
  • TORRANCE, Calif., Nov. 13, 2022 /PRNewswire/ --On November 12, 2022 Robinson Helicopter Company bid a final farewell to its founder, Frank Robinson.
  • One of the most recognizable names in the helicopter industry, Frank Robinson was a pioneer, a man not driven by reward or accolades but by a vision that redefined the industry and forever changed general aviation.
  • Six years later, defying critics and overcoming enormous obstacles, Robinson was granted FAA certification for his two-place, piston powered R22 helicopter.
  • In the early '90s, realizing the potential for a light mid-size helicopter, Robinson introduced the four-place piston powered R44.

Helicopter Pioneer Frank Robinson Passes

Retrieved on: 
Sunday, November 13, 2022

TORRANCE, Calif., Nov. 13, 2022 /PRNewswire/ --On November 12, 2022 Robinson Helicopter Company bid a final farewell to its founder, Frank Robinson.

Key Points: 
  • TORRANCE, Calif., Nov. 13, 2022 /PRNewswire/ --On November 12, 2022 Robinson Helicopter Company bid a final farewell to its founder, Frank Robinson.
  • One of the most recognizable names in the helicopter industry, Frank Robinson was a pioneer, a man not driven by reward or accolades but by a vision that redefined the industry and forever changed general aviation.
  • Six years later, defying critics and overcoming enormous obstacles, Robinson was granted FAA certification for his two-place, piston powered R22 helicopter.
  • In the early '90s, realizing the potential for a light mid-size helicopter, Robinson introduced the four-place piston powered R44.

Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors

Retrieved on: 
Wednesday, November 2, 2022

The trial enrolled 123 subjects with various types of pediatric central nervous system (CNS) tumors.

Key Points: 
  • The trial enrolled 123 subjects with various types of pediatric central nervous system (CNS) tumors.
  • Subjects between the ages of one month and 30 years of age were enrolled and received tozuleristide prior to their planned tumor resection.
  • A total of 9 clinical sites across the United States participated in the trial coordinated through the Pacific Pediatric Neuro-Oncology Consortium (PNOC).
  • The Canvas imaging system was developed and is manufactured by Teal Light Surgical, Inc., a wholly owned subsidiary of Blaze.

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

Retrieved on: 
Thursday, October 27, 2022

STAMFORD, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced updated research showing the clear benefits of rapid whole genome sequencing (rWGS) to diagnose critically ill newborns in the neonatal intensive care unit (NICU). The findings come from the recently completed first phase of the SeqFirst study, for which Sema4|GeneDx performed the sequencing, and was conducted in partnership with Seattle Children’s Hospital and the University of Washington. Tara Wenger, an attending physician at Seattle Children’s Hospital, will give a platform presentation at the American Society of Human Genetics (ASHG) Annual Meeting on October 28, 2022, to share research highlights.

Key Points: 
  • The findings come from the recently completed first phase of the SeqFirst study, for which Sema4|GeneDx performed the sequencing, and was conducted in partnership with Seattle Childrens Hospital and the University of Washington.
  • Abnormal rWGS results were found in 63% of the infants that were sequenced, and explanatory rWGS results resulted in a change in health management in 88% of cases overall.
  • Among the infants who received abnormal results, one-quarter were not suspected of having a genetic syndrome, emphasizing the value of broad-based testing.
  • For more information, please visit sema4.com and connect with us on LinkedIn , Twitter , Facebook , and Instagram .

Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 19, 2022

The presentations will highlight Umojas complementary cell therapy platforms for in vivo CAR T-cell therapeutics and RACR-induced cytotoxic lymphocytes (iCIL).

Key Points: 
  • The presentations will highlight Umojas complementary cell therapy platforms for in vivo CAR T-cell therapeutics and RACR-induced cytotoxic lymphocytes (iCIL).
  • VivoVec engineers patient T cells in vivo via surface-engineered lentivirus-mediated transduction using our proprietary 4th generation lentiviral vector technology.
  • VivoVec can also be applied in an ex vivo manufacturing setting where a traditional CAR T therapeutic approach is more appropriate.
  • Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives.

Torus Biosystems Announces Appointment of Nancy Hill to Board of Directors

Retrieved on: 
Wednesday, October 12, 2022

Torus Biosystems (Torus or the Company), the company pioneering molecular in vitro diagnostics for point of care use, today announced the appointment of Nancy Hill as lead Independent Director to the Companys Board of Directors.

Key Points: 
  • Torus Biosystems (Torus or the Company), the company pioneering molecular in vitro diagnostics for point of care use, today announced the appointment of Nancy Hill as lead Independent Director to the Companys Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20221012005202/en/
    Nancy Hill joins the Board of Directors of Torus Biosystems.
  • (Photo: Business Wire)
    Nancys experience in developing, commercializing, and scaling the distribution of innovative technologies to improve health outcomes aligns well with our mission, making her an ideal addition to the Torus Board of Directors, said Shawn Marcell, President and CEO of Torus.
  • Torus has the opportunity to deliver comprehensive, personalized, infectious disease diagnostics at the point of care in a truly revolutionary way, said Nancy Hill.

infodas receives NITES certification from the Cyber Security Agency of Singapore

Retrieved on: 
Tuesday, October 4, 2022

COLOGNE, Germany, Oct. 4, 2022 /PRNewswire/ -- infodas, leading provider of Cross Domain Solutions (CDS), announces that its SDoT Security Gateway has officially received the (National IT Evaluation Scheme) NITES certification from the prestigious Cyber Security Agengy of Singapore.

Key Points: 
  • COLOGNE, Germany, Oct. 4, 2022 /PRNewswire/ -- infodas, leading provider of Cross Domain Solutions (CDS), announces that its SDoT Security Gateway has officially received the (National IT Evaluation Scheme) NITES certification from the prestigious Cyber Security Agengy of Singapore.
  • The SDoT Security Gateway is engineered and produced in Germany in accordance with security design principles by security vetted staff.
  • The accreditation process was possible due to an intensive collaboration between our certification and project teams at the Cyber Security Agency (CSA) from Singapore.
  • The Cyber Security Agency (CSA) is a government agency under the Prime Minister's Office, and is managed by the Singapore Government's Ministry of Communications and Information.

infodas receives NITES certification from the Cyber Security Agency of Singapore

Retrieved on: 
Tuesday, October 4, 2022

COLOGNE, Germany, Oct. 4, 2022 /PRNewswire/ -- infodas, leading provider of Cross Domain Solutions (CDS), announces that its SDoT Security Gateway has officially received the (National IT Evaluation Scheme) NITES certification from the prestigious Cyber Security Agengy of Singapore.

Key Points: 
  • COLOGNE, Germany, Oct. 4, 2022 /PRNewswire/ -- infodas, leading provider of Cross Domain Solutions (CDS), announces that its SDoT Security Gateway has officially received the (National IT Evaluation Scheme) NITES certification from the prestigious Cyber Security Agengy of Singapore.
  • The SDoT Security Gateway is engineered and produced in Germany in accordance with security design principles by security vetted staff.
  • The accreditation process was possible due to an intensive collaboration between our certification and project teams at the Cyber Security Agency (CSA) from Singapore.
  • The Cyber Security Agency (CSA) is a government agency under the Prime Minister's Office, and is managed by the Singapore Government's Ministry of Communications and Information.